The Safety Act Takes Effect
The Act created a statutory framework for providing regenerative medicine, including plan review by certified committees and publication of provision plans [2].
Japan Medical Information Guide
Stem Cell “Anti-Aging” in Japan: Regulation, Evidence and Questions to Ask
Japan Medical is an independent information publisher. Japan Medical is not a hospital, clinic, laboratory, medical institution, healthcare provider or referral service. Japan Medical does not diagnose conditions, assess suitability, recommend procedures, arrange medical care or guarantee outcomes. This guide explains how regenerative-medicine records work in Japan and what to verify before relying on any claim.
Independent information publisher
Eleven official sources linked
Updated July 27, 2026
Written and edited by Japan Medical
Submission is not approvalA submitted provision plan is not the same as PMDA marketing approval.
Registration is not proofRegistration or committee review does not establish that a claimed benefit has been demonstrated.
Evidence must matchMatch the exact product, source, processing, route, dose, population and intended use.
Risk is not transferableRisk estimates cannot be transferred from a different product or protocol.
Information, not assessmentJapan Medical provides information and source-navigation support, not suitability assessments or medical recommendations.
Published by Japan Medical
About Japan Medical
Who Publishes This Guide, and Why
-
What Japan Medical does
Japan Medical publishes independent information guides. Japan Medical can help readers locate public records, understand terminology and prepare a neutral information checklist.
-
What Japan Medical does not do
Japan Medical does not diagnose conditions, assess suitability, recommend procedures, arrange medical care or guarantee outcomes.
-
How content is produced
Each guide is written against official records, and every regulatory statement carries a numbered link so readers can check the original document [1].
-
Publishing record
Publisher: Japan Medical. Author: Japan Medical. Content editor: Japan Medical. Source review by Japan Medical.
-
Update policy
Last updated: July 27, 2026. The next source review is planned for the fourth quarter of 2026, or sooner if a cited official record changes.
Regulatory Timeline
The Framework Changed in 2025
Japan’s Act on the Safety of Regenerative Medicine took effect in 2014, and an amended framework entered into force on May 31, 2025 [2]. Older articles that describe only the 2014 system may be out of date.
The Amended Framework Enters Into Force
An amendment to the framework took effect on this date [2]. Confirm that any provider’s documents reflect the amended rules, not only the original 2014 text.
Current Source Check for This Guide
The official records cited here were last checked on July 27, 2026. Registries change continuously; open the linked record itself before relying on an entry.
Three Different Statuses
A Plan, a Study and an Approval Are Not the Same Record
Three kinds of records appear in discussions of regenerative medicine in Japan. They answer different questions.
0Year the safety Act took effect [2]
0Year the amended framework entered into force [2]
0Official sources linked below
0Record fields to verify
A. Provision Plan
A regenerative-medicine provision plan is part of a statutory submission and publication procedure [3]. It is not a product marketing approval, and committee review of a plan is not a government judgment that the service works [4].
B. Registered Clinical Research
Clinical research can be searched in the jRCT system, including the study objective, status and participating institutions [5]. Registration describes an existing study; it does not show positive results.
C. PMDA-Approved Product
A PMDA approval applies to a specific product, for a specific intended use, under a specific review decision [6]. Approval of one product transfers nothing to others.
Why the Distinction Matters
Marketing often presents a plan record as if it were an approval. Identify which record type any document is, then read only the conclusions that record type can support.
A marketing term, examined rather than endorsed
Terminology First
What “Anti-Aging” Means on This Page
-
Why the quotation marks
“Anti-aging” appears in quotation marks because it is a marketing term and service category discussed on this page, not a defined medical indication and not an endorsement of effect [10].
-
What the term does not define
The phrase does not specify a product, a cell source, a dose or a route of administration. Two services using the same phrase may involve entirely different preparations and entirely different evidence situations.
-
What to ask instead
Replace the label with concrete questions: which exact product is proposed, for which intended use, supported by which study or approval record? A precise answer can be verified; a slogan cannot.
-
Honors do not transfer
Japan’s research honors, including the 2012 Nobel Prize for iPS cell work, belong to specific discoveries. An award attached to one discovery cannot serve as evidence for a different product or an “anti-aging” service [10].
Evidence Matching
Does the Evidence Match the Proposed Service?
Check whether any study you are shown matches the service actually proposed, field by field. Evidence involving a different product, processing method, route, population or intended use should not be presented as proof for the proposed service [10].
Exact Product or Preparation
The named product, not a category or a slogan.
Cell or Material Source
The tissue type and origin of the material used.
Autologous or Allogeneic
Own cells or donor cells; the evidence differs.
Processing and Manufacturing
How the preparation is made and controlled.
Dose or Quantity
The amount administered, not a headline number.
Route of Administration
How it enters the body; risk differs by route.
Study Population
Who was studied: age, condition and health status.
Comparator
What the preparation was compared against.
Outcome Measures
Which endpoints were measured, and were they predefined?
Follow-Up Duration
How long participants were observed after administration.
Source review by Japan Medical
Evidence Quality
Six Questions About Any Study You Are Shown
-
Study design
A randomized controlled design answers different questions than an observational report or case series. Ask which design was used and why it fits the claim.
-
Sample size
Very small studies can produce hopeful patterns that vanish in larger groups. Ask how many participants completed the protocol.
-
Population fit
Results from one age group or condition may say little about another. Ask how closely the studied population matches yours.
-
Comparator
Without a comparison group, improvement cannot be separated from natural variation or placebo effects. Ask what it was compared against.
-
Outcome measures
Ask which endpoints were defined before the study began and whether they were objective or subjective.
-
Follow-up
Short observation windows miss late effects. Ask how long participants were followed and how many left early.
Risks and Uncertainty
Risk Questions Organized by Category
Risk profiles differ between products and protocols, and no page can list rates without an identified provider and current documents. FDA material is cited as a general statement of risk principles, not a conclusion about any Japanese provider [9]. Also read current PMDA safety information [7].
-
Contamination or infection controls
Ask how sterility is maintained and tested, and what happens if a test fails [9].
-
Immune or inflammatory reactions
Ask how reactions are screened for and managed, especially with donor-derived material.
-
Procedure-related complications
Collection and administration each carry their own risks. Ask for both lists separately.
-
Abnormal tissue growth or tumor concerns
Ask what is known and uncertain for the exact cell type proposed [9].
-
Thrombosis or administration-related risks
Risks differ by route; ask for the route-specific risk discussion.
-
Uncertainty from limited follow-up
Where long-term data is thin, the consent document should say so.
-
Emergency response arrangements
Ask what happens if something goes wrong, and who responds.
-
Adverse-event reporting
Ask how adverse events are recorded and reported, and how you would be informed.
-
Follow-up provider and location
Ask who provides follow-up care, where, and what happens after you return home.
-
Compensation or insurance arrangements
Ask what compensation or insurance applies if harm occurs, and request the terms in writing.
Provider and Record Verification
Fifteen Fields to Check in the Official Records
Cross-check claims against the MHLW plan database, the committee information and the jRCT registry [3] [4] [5]. This page does not name or recommend any hospital, clinic, doctor or provider.
Provider’s Exact Legal Name
Match the registered entity, not a brand name.
Facility Name
Where the service is actually provided.
Provision-Plan Title
The exact title in the database.
Plan or Record Number
The identifier tying claim to record.
First Publication Date
When the record first appeared.
Latest Update Date
Whether the record is still maintained.
Current Status
Active, changed or withdrawn; do not assume.
Regenerative-Medicine Classification
The risk class the plan was filed under.
Reviewing Committee Name
Which certified committee reviewed the plan.
Committee Certification Number
Confirm the committee itself is certified [4].
Current Consent-Document Version
Ask for the version date before reading.
Proposed Product or Material
The exact preparation named in the record.
Route of Administration
Confirm the route matches what you were told.
Follow-Up and Adverse-Event Contact
A named channel for problems after the fact.
Total Cost and Cancellation Terms
In writing, before any payment or travel.
Paper first, decisions later
Documents to Request
Ask for These Before Any Payment or Travel
-
The current consent document
Read the version date. It should state known and uncertain risks, alternatives and follow-up arrangements in a language you understand.
-
The provision-plan identifiers
Plan title, record number, publication dates and reviewing committee, so you can find the same entry yourself [3].
-
A written product description
The exact preparation, its source and processing method, specific enough to compare against research records.
-
Itemized costs and cancellation terms
Total price, inclusions, exclusions, and refund rules if you cancel or the plan changes.
-
Follow-up and adverse-event contacts
Who to contact, through which channel and in which language, if a problem appears after you return home.
Practical Questions
Costs, Follow-Up and Cross-Border Practicalities
Practical arrangements matter when the service and your home are in different countries.
Total Cost, Itemized
Ask for one document listing every component: assessments, collection, processing, administration, follow-up and repeat visits. A single headline price hides important decisions.
Cancellation and Refunds
Ask what happens to your payment if you cancel before collection, after collection but before administration, or if the provider changes the plan.
Follow-Up Across Borders
Ask who handles follow-up once you leave Japan, how results are communicated, and what your physician at home would need to know.
Language of the Record
Consent documents and plan records carry legal weight. Confirm you will receive versions in a language you read fluently before signing.
Marketing Red Flags
Phrases That Deserve a Second Look
Health claims should be judged by the evidence behind them, not their confidence [10]. Testimonials, before-and-after images, ratings, countdowns and scarcity claims are not evidence.
“Government-Approved Treatment”
Neutral reading: a provision plan may have been submitted under the statutory framework. Plan submission is not the same as PMDA marketing approval.
“Safe and Effective”
Neutral reading: safety and effectiveness must be evaluated for the exact product, intended use, protocol and supporting evidence.
“Advanced Anti-Aging Therapy”
Neutral reading: a service marketed using the term “anti-aging.” The term does not itself establish a defined indication or demonstrated benefit.
“Clinically Proven”
Neutral reading: studied under a specified protocol in a specified population. Use stronger wording only when the evidence supports it.
“No Side Effects, Guaranteed Outcome”
Neutral reading: outcomes and risks vary between individuals and protocols. Request known and uncertain risks in writing.
“Limited Availability, Book Now”
Neutral reading: urgency is a sales technique. Decisions about health services should be made on documents, not deadlines.
Terminology by Category
Words That Belong to Different Categories
-
A. Source relationship
Autologous and allogeneic describe where material comes from: the same person or a donor. The words describe origin, not effectiveness.
-
B. Cell-based preparations
Stem-cell preparations and NK-cell preparations involve living cells, each with its own regulatory and evidence questions.
-
C. Cell-free or secreted-material descriptions
Exosomes, conditioned media and culture supernatant are distinct from cell therapies, and “cell-free” does not mean safer or better supported [8].
-
D. Blood-derived procedures
PRP is prepared from a person’s own blood, a different category from cell culture with its own evidence questions.
-
E. Regulatory or evidence status
Provision plan, clinical research and approved product describe status, not product types. A category name proves nothing about safety, effectiveness or approval status.
Same sentence, different categories: do not mix them
Official Source Directory
Every Source Behind This Guide, and What to Check There
Directory last checked July 27, 2026.
Google Search Central
How people-first health content is judged: who, how and why.
Read the guidanceMHLW Law and Amendment
The current legal framework, including the 2025 amendment.
Read the framework pageMHLW Plan Database
Search provision plans by provider, title and status.
Search the databaseCertified Committees
How certified committees review provision plans.
Read the MHLW pagejRCT Registry
Search registered clinical research: objectives, status, institutions.
Search the registryPMDA Review Reports
Review reports and approval details for specific products.
View review reportsPMDA Safety Information
Safety updates and attachments for regenerative products.
View safety updatesMHLW Exosome Notice
MHLW’s notice on exosome-related products and promotion.
Read the noticeFDA Consumer Information
General consumer risk principles for regenerative therapies.
Read the FDA pageFTC Health Claims Guidance
Evidence standards expected behind health claims.
Read the FTC guidancePPC Sensitive Data
Japan’s sensitive personal information rules.
Read the PPC FAQCommon Questions
Questions Readers Ask
Why does this page put “anti-aging” in quotation marks?
The phrase is a marketing term and service category, not a defined medical indication. Quotation marks signal that this guide discusses the term and the claims built around it; using the phrase is not an endorsement of any effect. The guide examines regulation, evidence and verification instead of promoting a service.
Can Japan Medical tell me whether a service is right for me?
No. Suitability depends on your individual health situation and can only be assessed by a licensed healthcare professional who examines you in person. Japan Medical can help you locate official public records, understand terminology and prepare a neutral list of questions to bring to that professional.
How often is this guide updated?
The source directory on this page shows the date of the most recent source check. The guide is reviewed when a cited official record changes, and a routine source review is planned at regular intervals. If you rely on a specific fact, open the linked official record to confirm it is still current.
What should I avoid sending in a first message?
Do not send medical records, diagnostic reports, identification documents, images of prescriptions or detailed health histories in an initial inquiry. Describe only what information you are looking for and nothing more at this stage. Health-related details are treated as sensitive personal information under Japan’s data-protection framework [11].
A provider showed me an approval document. What should I check?
First identify what kind of document it is: a provision-plan record, a research registration or a PMDA product approval. Then match the exact product name and intended use against the official record. A plan printout or a committee letter is not a product approval, and an approval for one product does not cover a different service [6].
Next Steps
Need Help Organizing the Information?
Japan Medical can help you locate official public records, understand terminology and prepare a neutral list of questions. Japan Medical does not assess suitability, recommend providers or arrange medical care. Please do not send medical records, diagnostic reports, identification documents, images of prescriptions or detailed health histories in an initial inquiry [11].
Japan Medical provides information and source-navigation support. It does not assess suitability, recommend providers or arrange medical care.